Gen House

Established in 2014 and based in Suzhou, China, Genhouse Bio Co. , Ltd. , trading under the name Gen House, operates as a biotechnology company focusing on the development of small molecule antitumor new drugs. Kuifeng Wang, the company's founder and CEO, graduated from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and is also a candidate for the National Major Talent Project.

It has a branch office in Shanghai. The company cooperated with Zhejiang University, Wuxi AppTec, Shanghai Institute of Material Medica, Chinese Academy of Sciences. In 2020, the company reached a cooperation with Huya International to realize commercialization in the early stage of drug development. In January 2026, the firm raised over CNY 300 million in venture funding led by Green Pine Capital Partners.

Gen House mainly engages in the research and development of small molecule antitumor new drugs. The company has established a structural biology research platform, an early drug screening platform, and a preclinical evaluation platform, forming a product pipeline with targeted antitumor products as the core. Its main products include GH35, GH21, GH55 and GH52, etc. GH21 is a small molecule SHP2 inhibitor.

The company generates revenue by providing small molecule antitumor new drugs. The company plans to use the latest venture funds to accelerate the research and development of its AI anti-tumor small molecule pipeline, specifically advancing its differentiated programs in the Ras signaling and synthetic lethality fields.